Two mass spectrometry systems for the MHRA come from Thermo Fisher
- Medicines and Healthcare products Regulatory Agency (MHRA)
- Open procedure, 1 bid
- 18 November 2026 to 18 November 2031
The Medicines and Healthcare products Regulatory Agency (MHRA) is buying two mass spectrometry systems from Thermo Fisher Scientific.
The new systems will replace two triple quad mass spectrometers, and servicing and any bespoke consumables come with them. They will be used to measure and characterise biological medicine standards, influenza among them, and to examine counterfeit and sub-potent medicines. One system pairs a high-resolution mass spectrometer with low-flow liquid chromatography, for work such as proteomics and therapeutic antibodies. The other pairs a triple quadrupole instrument with UPLC for targeted measurement at high throughput.
The open tender drew one bid, with technical worth 65% of the score, commercial 25% and social value 10%. Thermo Fisher won the £1.2m contract in October 2026. It will run for five years, to November 2031.
Contract ends November 2031
- What
- Mass spectrometry and chromatography systems
- Supplier
- Thermo Fisher Scientific
- Value
- £1.2m
- How it was bought
- Open procedure
- 1 bid
- Dates and next
- Nov 2026 to Nov 2031